5722 related articles for article (PubMed ID: 12068308)
1. Mutations of the BRAF gene in human cancer.
Davies H; Bignell GR; Cox C; Stephens P; Edkins S; Clegg S; Teague J; Woffendin H; Garnett MJ; Bottomley W; Davis N; Dicks E; Ewing R; Floyd Y; Gray K; Hall S; Hawes R; Hughes J; Kosmidou V; Menzies A; Mould C; Parker A; Stevens C; Watt S; Hooper S; Wilson R; Jayatilake H; Gusterson BA; Cooper C; Shipley J; Hargrave D; Pritchard-Jones K; Maitland N; Chenevix-Trench G; Riggins GJ; Bigner DD; Palmieri G; Cossu A; Flanagan A; Nicholson A; Ho JW; Leung SY; Yuen ST; Weber BL; Seigler HF; Darrow TL; Paterson H; Marais R; Marshall CJ; Wooster R; Stratton MR; Futreal PA
Nature; 2002 Jun; 417(6892):949-54. PubMed ID: 12068308
[TBL] [Abstract][Full Text] [Related]
2. Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.
Deichmann M; Thome M; Benner A; Kirschner M; Hassanzadeh J; Kurzen H
BMC Cancer; 2005 Jun; 5():58. PubMed ID: 15935100
[TBL] [Abstract][Full Text] [Related]
3. Revisiting the Role of B-RAF Kinase as a Therapeutic Target in Melanoma.
Kozyra P; Pitucha M
Curr Med Chem; 2024; 31(15):2003-2020. PubMed ID: 37855341
[TBL] [Abstract][Full Text] [Related]
4. Computational algorithms for in silico profiling of activating mutations in cancer.
Jordan EJ; Patil K; Suresh K; Park JH; Mosse YP; Lemmon MA; Radhakrishnan R
Cell Mol Life Sci; 2019 Jul; 76(14):2663-2679. PubMed ID: 30982079
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Wan PT; Garnett MJ; Roe SM; Lee S; Niculescu-Duvaz D; Good VM; Jones CM; Marshall CJ; Springer CJ; Barford D; Marais R;
Cell; 2004 Mar; 116(6):855-67. PubMed ID: 15035987
[TBL] [Abstract][Full Text] [Related]
6. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Chapman PB; Hauschild A; Robert C; Haanen JB; Ascierto P; Larkin J; Dummer R; Garbe C; Testori A; Maio M; Hogg D; Lorigan P; Lebbe C; Jouary T; Schadendorf D; Ribas A; O'Day SJ; Sosman JA; Kirkwood JM; Eggermont AM; Dreno B; Nolop K; Li J; Nelson B; Hou J; Lee RJ; Flaherty KT; McArthur GA;
N Engl J Med; 2011 Jun; 364(26):2507-16. PubMed ID: 21639808
[TBL] [Abstract][Full Text] [Related]
7. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Hauschild A; Grob JJ; Demidov LV; Jouary T; Gutzmer R; Millward M; Rutkowski P; Blank CU; Miller WH; Kaempgen E; Martín-Algarra S; Karaszewska B; Mauch C; Chiarion-Sileni V; Martin AM; Swann S; Haney P; Mirakhur B; Guckert ME; Goodman V; Chapman PB
Lancet; 2012 Jul; 380(9839):358-65. PubMed ID: 22735384
[TBL] [Abstract][Full Text] [Related]
8. Mutations of the BRAF gene in human cancer, by Davies et al. (Nature 2002; 417: 949-54).
Millington GW
Clin Exp Dermatol; 2013 Mar; 38(2):222-3. PubMed ID: 23397951
[No Abstract] [Full Text] [Related]
9. A landscape of driver mutations in melanoma.
Hodis E; Watson IR; Kryukov GV; Arold ST; Imielinski M; Theurillat JP; Nickerson E; Auclair D; Li L; Place C; Dicara D; Ramos AH; Lawrence MS; Cibulskis K; Sivachenko A; Voet D; Saksena G; Stransky N; Onofrio RC; Winckler W; Ardlie K; Wagle N; Wargo J; Chong K; Morton DL; Stemke-Hale K; Chen G; Noble M; Meyerson M; Ladbury JE; Davies MA; Gershenwald JE; Wagner SN; Hoon DS; Schadendorf D; Lander ES; Gabriel SB; Getz G; Garraway LA; Chin L
Cell; 2012 Jul; 150(2):251-63. PubMed ID: 22817889
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mutated, activated BRAF in metastatic melanoma.
Flaherty KT; Puzanov I; Kim KB; Ribas A; McArthur GA; Sosman JA; O'Dwyer PJ; Lee RJ; Grippo JF; Nolop K; Chapman PB
N Engl J Med; 2010 Aug; 363(9):809-19. PubMed ID: 20818844
[TBL] [Abstract][Full Text] [Related]
11. BRAF and RAS mutations in human lung cancer and melanoma.
Brose MS; Volpe P; Feldman M; Kumar M; Rishi I; Gerrero R; Einhorn E; Herlyn M; Minna J; Nicholson A; Roth JA; Albelda SM; Davies H; Cox C; Brignell G; Stephens P; Futreal PA; Wooster R; Stratton MR; Weber BL
Cancer Res; 2002 Dec; 62(23):6997-7000. PubMed ID: 12460918
[TBL] [Abstract][Full Text] [Related]
12. Distinct sets of genetic alterations in melanoma.
Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
[TBL] [Abstract][Full Text] [Related]
13. Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D;
N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011
[TBL] [Abstract][Full Text] [Related]
14. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
[TBL] [Abstract][Full Text] [Related]
15. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
Flaherty KT; Infante JR; Daud A; Gonzalez R; Kefford RF; Sosman J; Hamid O; Schuchter L; Cebon J; Ibrahim N; Kudchadkar R; Burris HA; Falchook G; Algazi A; Lewis K; Long GV; Puzanov I; Lebowitz P; Singh A; Little S; Sun P; Allred A; Ouellet D; Kim KB; Patel K; Weber J
N Engl J Med; 2012 Nov; 367(18):1694-703. PubMed ID: 23020132
[TBL] [Abstract][Full Text] [Related]
16. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
Sosman JA; Kim KB; Schuchter L; Gonzalez R; Pavlick AC; Weber JS; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Hersey P; Kefford R; Lawrence D; Puzanov I; Lewis KD; Amaravadi RK; Chmielowski B; Lawrence HJ; Shyr Y; Ye F; Li J; Nolop KB; Lee RJ; Joe AK; Ribas A
N Engl J Med; 2012 Feb; 366(8):707-14. PubMed ID: 22356324
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Bollag G; Hirth P; Tsai J; Zhang J; Ibrahim PN; Cho H; Spevak W; Zhang C; Zhang Y; Habets G; Burton EA; Wong B; Tsang G; West BL; Powell B; Shellooe R; Marimuthu A; Nguyen H; Zhang KY; Artis DR; Schlessinger J; Su F; Higgins B; Iyer R; D'Andrea K; Koehler A; Stumm M; Lin PS; Lee RJ; Grippo J; Puzanov I; Kim KB; Ribas A; McArthur GA; Sosman JA; Chapman PB; Flaherty KT; Xu X; Nathanson KL; Nolop K
Nature; 2010 Sep; 467(7315):596-9. PubMed ID: 20823850
[TBL] [Abstract][Full Text] [Related]
18. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
Heidorn SJ; Milagre C; Whittaker S; Nourry A; Niculescu-Duvas I; Dhomen N; Hussain J; Reis-Filho JS; Springer CJ; Pritchard C; Marais R
Cell; 2010 Jan; 140(2):209-21. PubMed ID: 20141835
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
20. Genetic predictors of MEK dependence in non-small cell lung cancer.
Pratilas CA; Hanrahan AJ; Halilovic E; Persaud Y; Soh J; Chitale D; Shigematsu H; Yamamoto H; Sawai A; Janakiraman M; Taylor BS; Pao W; Toyooka S; Ladanyi M; Gazdar A; Rosen N; Solit DB
Cancer Res; 2008 Nov; 68(22):9375-83. PubMed ID: 19010912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
